Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma.

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma.

Journal: bioRxiv : the preprint server for biology
Published: December 03, 2025

Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas.

Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas.

Journal: Expert opinion on investigational drugs
Published: September 11, 2025

Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1.

Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1.

Journal: Cancer chemotherapy and pharmacology
Published: July 17, 2025

Comment on: "selumetinib use as targeted therapy for plexiform neurofibroma: a comprehensive review of the literature" - mirdametinib as the emerging standard in NF1-PN.

Comment on: "selumetinib use as targeted therapy for plexiform neurofibroma: a comprehensive review of the literature" - mirdametinib as the emerging standard in NF1-PN.

Journal: Orbit (Amsterdam, Netherlands)
Published: July 09, 2025

Correction: Mirdametinib: First Approval.

Correction: Mirdametinib: First Approval.

Journal: Drugs
Published: June 25, 2025

Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma.

Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 21, 2025

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.

Journal: Pigment cell & melanoma research
Published: May 12, 2025

High-content microscopy and machine learning characterize a cell morphology signature of NF1 genotype in Schwann cells.

High-content microscopy and machine learning characterize a cell morphology signature of NF1 genotype in Schwann cells.

Journal: bioRxiv : the preprint server for biology
Published: April 28, 2025

Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.

Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.

Journal: Cells
Published: April 23, 2025

Mirdametinib (Gomekli) for neurofibromatosis type 1.

Mirdametinib (Gomekli) for neurofibromatosis type 1.

Journal: The Medical letter on drugs and therapeutics
Published: April 20, 2025

Mirdametinib: First Approval.

Mirdametinib: First Approval.

Journal: Drugs
Published: April 13, 2025

Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery.

Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery.

Journal: Angewandte Chemie (International ed. in English)
Published: April 04, 2025
Showing 1-12 of 40

Last Updated: 01/07/2026